Published in J Cell Sci on August 12, 2003
The interaction of IQGAP1 with the exocyst complex is required for tumor cell invasion downstream of Cdc42 and RhoA. J Cell Biol (2008) 2.39
MT1-MMP proinvasive activity is regulated by a novel Rab8-dependent exocytic pathway. EMBO J (2007) 2.16
Autoantigen Golgin-97, an effector of Arl1 GTPase, participates in traffic from the endosome to the trans-golgi network. Mol Biol Cell (2004) 1.62
Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic in human endothelial cells. Mol Biol Cell (2003) 1.39
Establishment and validation of computational model for MT1-MMP dependent ECM degradation and intervention strategies. PLoS Comput Biol (2012) 1.33
Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP. Mol Biol Cell (2006) 1.26
The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am J Pathol (2009) 1.17
The regulation of MMP targeting to invadopodia during cancer metastasis. Front Cell Dev Biol (2015) 1.11
Phosphorylation of membrane type 1-matrix metalloproteinase (MT1-MMP) and its vesicle-associated membrane protein 7 (VAMP7)-dependent trafficking facilitate cell invasion and migration. J Biol Chem (2011) 1.11
Coupling protein engineering with probe design to inhibit and image matrix metalloproteinases with controlled specificity. J Am Chem Soc (2013) 1.10
New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies. Biochem Res Int (2010) 1.07
A RAB5/RAB4 recycling circuitry induces a proteolytic invasive program and promotes tumor dissemination. J Cell Biol (2014) 1.04
Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells. J Cell Sci (2013) 1.04
The second dimer interface of MT1-MMP, the transmembrane domain, is essential for ProMMP-2 activation on the cell surface. J Biol Chem (2008) 0.99
Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev (2012) 0.95
Interruption of endothelin signaling modifies membrane type 1 matrix metalloproteinase activity during ischemia and reperfusion. Am J Physiol Heart Circ Physiol (2007) 0.93
Actin-associated protein palladin promotes tumor cell invasion by linking extracellular matrix degradation to cell cytoskeleton. Mol Biol Cell (2014) 0.91
The inactive 44-kDa processed form of membrane type 1 matrix metalloproteinase (MT1-MMP) enhances proteolytic activity via regulation of endocytosis of active MT1-MMP. J Biol Chem (2008) 0.90
Hematopoietic Stem Cell Mobilization and Homing after Transplantation: The Role of MMP-2, MMP-9, and MT1-MMP. Biochem Res Int (2012) 0.89
Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen. Mol Cancer Res (2009) 0.89
VANGL2 regulates membrane trafficking of MMP14 to control cell polarity and migration. J Cell Sci (2012) 0.89
Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase. J Biol Chem (2010) 0.88
YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. Biochem Biophys Res Commun (2010) 0.88
MT-LOOP-dependent localization of membrane type I matrix metalloproteinase (MT1-MMP) to the cell adhesion complexes promotes cancer cell invasion. J Biol Chem (2013) 0.87
Regulation of MT1-MMP activity by β-catenin in MDCK non-cancer and HT1080 cancer cells. J Cell Physiol (2010) 0.87
Membrane type 1 matrix metalloproteinase (MT1-MMP) ubiquitination at Lys581 increases cellular invasion through type I collagen. J Biol Chem (2012) 0.87
Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase. Biochem J (2005) 0.87
Alterations in membrane type-1 matrix metalloproteinase abundance after the induction of thoracic aortic aneurysm in a murine model. Am J Physiol Heart Circ Physiol (2010) 0.86
NEDD9 depletion leads to MMP14 inactivation by TIMP2 and prevents invasion and metastasis. Mol Cancer Res (2013) 0.86
Retinal pigment epithelium protection from oxidant-mediated loss of MMP-2 activation requires both MMP-14 and TIMP-2. Invest Ophthalmol Vis Sci (2006) 0.85
Essential role of endocytosis of the type II transmembrane serine protease TMPRSS6 in regulating its functionality. J Biol Chem (2011) 0.83
Non-destructive and selective imaging of the functionally active, pro-invasive membrane type-1 matrix metalloproteinase (MT1-MMP) enzyme in cancer cells. J Biol Chem (2013) 0.83
Distinct interactions with cellular E-cadherin of the two virulent metalloproteinases encoded by a Bacteroides fragilis pathogenicity island. PLoS One (2014) 0.82
Quantitative FRET imaging to visualize the invasiveness of live breast cancer cells. PLoS One (2013) 0.82
MT1-MMP hemopexin domain exchange with MT4-MMP blocks enzyme maturation and trafficking to the plasma membrane in MCF7 cells. Biochem J (2006) 0.81
Peptide aptamers as new tools to modulate clathrin-mediated internalisation--inhibition of MT1-MMP internalisation. BMC Cell Biol (2010) 0.81
BST-2 binding with cellular MT1-MMP blocks cell growth and migration via decreasing MMP2 activity. J Cell Biochem (2012) 0.81
Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases. J Biol Chem (2011) 0.81
Sorting nexin 9 negatively regulates invadopodia formation and function in cancer cells. J Cell Sci (2016) 0.80
Mechanical control of spheroid growth: distinct morphogenetic regimes. J Biomech (2011) 0.78
The planar cell polarity protein VANGL2 coordinates remodeling of the extracellular matrix. Commun Integr Biol (2012) 0.78
MicroRNA miR-182 cluster mediated modulation of RECK without changes in cell surface membrane type-1 matrix metalloproteinase (MT1-MMP). Am J Cancer Res (2015) 0.77
Clonal expansion of T cells in abdominal aortic aneurysm: a role for doxycycline as drug of choice? Int J Mol Sci (2015) 0.77
NEDD9/Arf6-dependent endocytic trafficking of matrix metalloproteinase 14: a novel mechanism for blocking mesenchymal cell invasion and metastasis of breast cancer. Oncogene (2014) 0.77
Hic-5 mediates the initiation of endothelial sprouting by regulating a key surface metalloproteinase. J Cell Sci (2016) 0.77
A new front in cell invasion: The invadopodial membrane. Eur J Cell Biol (2016) 0.76
mDia1 regulates breast cancer invasion by controlling membrane type 1-matrix metalloproteinase localization. Oncotarget (2016) 0.76
Beta2-adaptin binds actopaxin and regulates cell spreading, migration and matrix degradation. PLoS One (2012) 0.76
MT1-MMP: Endosomal delivery drives breast cancer metastasis. J Cell Biol (2015) 0.76
Rat forming incisor requires a rigorous ECM remodeling modulated by MMP/RECK balance. J Mol Histol (2009) 0.76
RABGTPases in MT1-MMP trafficking and cell invasion: Physiology versus pathology. Small GTPases (2015) 0.75
MT1-MMP Inhibits the Activity of Bst-2 via Their Cytoplasmic Domains Dependent Interaction. Int J Mol Sci (2016) 0.75
The roles and implications of exosomes in sarcoma. Cancer Metastasis Rev (2016) 0.75
The role of Tks adaptor proteins in invadopodia formation, growth and metastasis of melanoma. Oncotarget (2016) 0.75
Metalloproteinase binding proteins: WO2009097397. Expert Opin Ther Pat (2010) 0.75
Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis. Oncotarget (2016) 0.75
Proactive for invasion: Reuse of matrix metalloproteinase for structural memory. J Cell Biol (2016) 0.75
Post-Translational Modification of the Membrane Type 1 Matrix Metalloproteinase (MT1-MMP) Cytoplasmic Tail Impacts Ovarian Cancer Multicellular Aggregate Dynamics. J Biol Chem (2017) 0.75
Peripheral Membrane Associations of Matrix Metalloproteinases. Biochim Biophys Acta (2017) 0.75
VANGL2 interacts with integrin αv to regulate matrix metalloproteinase activity and cell adhesion to the extracellular matrix. Exp Cell Res (2017) 0.75
Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res (2006) 8.26
Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci (2002) 4.23
A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med (2003) 3.20
Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell (2006) 2.43
ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci (2005) 1.99
Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochem J (2010) 1.93
Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc Res (2005) 1.77
Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci (2002) 1.69
Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem (2005) 1.59
ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem Biophys Res Commun (2002) 1.55
Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell migration. J Biol Chem (2007) 1.50
Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1. Proc Natl Acad Sci U S A (2012) 1.46
Matrix metalloproteinases in disease and repair processes in the anterior segment. Surv Ophthalmol (2002) 1.41
Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem (2006) 1.34
Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR). J Biol Chem (2003) 1.32
Human diabetic corneas preserve wound healing, basement membrane, integrin and MMP-10 differences from normal corneas in organ culture. Exp Eye Res (2003) 1.26
Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci U S A (2011) 1.26
Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J Biol Chem (2004) 1.24
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res (2002) 1.23
Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem (2002) 1.22
Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration. J Biol Chem (2007) 1.22
The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol (2008) 1.21
Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol (2009) 1.20
Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem (2004) 1.18
Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes. Arthritis Res Ther (2011) 1.15
Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol (2005) 1.14
The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett (2002) 1.13
Increased matrix metalloproteinase-13 production with aging by human articular chondrocytes in response to catabolic stimuli. J Gerontol A Biol Sci Med Sci (2005) 1.13
Temporal and spatial expression of matrix metalloproteinases during wound healing of human corneal tissue. Exp Eye Res (2003) 1.13
A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis. PLoS One (2012) 1.12
Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1. J Biol Chem (2007) 1.09
Distinct roles of dopamine and subthalamic nucleus in learning and probabilistic decision making. Brain (2012) 1.07
The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function. Biochemistry (2010) 1.06
Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. Cancer Res (2006) 1.04
Phosphorylation-dependent interactions between ADAM15 cytoplasmic domain and Src family protein-tyrosine kinases. J Biol Chem (2001) 1.04
Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition. J Biol Chem (2004) 1.03
Cell cycle regulation of pEg3, a new Xenopus protein kinase of the KIN1/PAR-1/MARK family. Dev Biol (2002) 1.02
The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3. FEBS Lett (2002) 1.02
Unveiling the surface epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase. J Biol Chem (2003) 1.02
Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb Haemost (2002) 1.01
Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}-converting enzyme. J Biol Chem (2005) 1.01
TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is modulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4. J Biol Chem (2007) 1.01
Family-based investigation of the C677T polymorphism of the methylenetetrahydrofolate reductase gene in ischaemic heart disease. Atherosclerosis (2002) 1.01
Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical. Cancer Res (2005) 1.00
Membrane type-1 matrix metalloproteinase activity is regulated by the endocytic collagen receptor Endo180. J Cell Sci (2009) 1.00
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics (2003) 1.00
Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA. J Thorac Oncol (2010) 1.00
Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Lett (2002) 0.99
Human corneal epithelial cells require MMP-1 for HGF-mediated migration on collagen I. Invest Ophthalmol Vis Sci (2003) 0.98
MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci (2010) 0.97
Lactoferricin mediates anabolic and anti-catabolic effects in the intervertebral disc. J Cell Physiol (2012) 0.97
Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha-converting enzyme. Biochem J (2002) 0.96
Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS One (2012) 0.95
Differential expression of matrix metalloproteinases during impaired wound healing of the diabetes mouse. J Invest Dermatol (2002) 0.94
Role of the netrin-like domain of procollagen C-proteinase enhancer-1 in the control of metalloproteinase activity. J Biol Chem (2010) 0.93
Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). Biochem J (2003) 0.92
Use of a multiple-enzyme/multiple-reagent assay system to quantify activity levels in samples containing mixtures of matrix metalloproteinases. Biochemistry (2004) 0.92
Matrix metalloproteinases at a glance. J Cell Sci (2004) 0.92
Delineating the molecular basis of the inactivity of tissue inhibitor of metalloproteinase-2 against tumor necrosis factor-alpha-converting enzyme. J Biol Chem (2004) 0.92
ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int J Cancer (2006) 0.90
Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases 1 in plasma by immunoassay. Clin Chem (2002) 0.89
The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition. Biochem J (2008) 0.89
Sorsby's fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP-3) mutants have unimpaired matrix metalloproteinase inhibitory activities, but affect cell adhesion to the extracellular matrix. Matrix Biol (2002) 0.88
Photoletter to the editor: Oral ulceration in pyoderma gangrenosum. J Dermatol Case Rep (2011) 0.88
Pentosan polysulfate increases affinity between ADAMTS-5 and TIMP-3 through formation of an electrostatically driven trimolecular complex. Biochem J (2012) 0.87
Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness. J Pathol (2011) 0.87
Membrane type 1 matrix metalloproteinase (MT1-MMP) ubiquitination at Lys581 increases cellular invasion through type I collagen. J Biol Chem (2012) 0.87
Membrane-type 1 matrix metalloproteinase stimulates cell migration through epidermal growth factor receptor transactivation. Mol Cancer Res (2007) 0.87
Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2). Biochem J (2010) 0.87
New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorg Med Chem (2004) 0.86
Membrane type 1-matrix metalloproteinase induces endothelial cell morphogenic differentiation by a caspase-dependent mechanism. Exp Cell Res (2005) 0.85
Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP-1 as the scaffold: a new frontier in TIMP engineering. Protein Sci (2002) 0.85
Establishment and characterization of 7 new monoclonal antibodies to tissue inhibitor of metalloproteinases-1. Tumour Biol (2005) 0.85
The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment. Cancer Lett (2009) 0.84
Granulocyte-macrophage colony stimulating factor induces endothelial capillary formation through induction of membrane-type 1 matrix metalloproteinase expression in vitro. Int J Cancer (2008) 0.84
Cellular cholesterol regulates MT1 MMP dependent activation of MMP 2 via MEK-1 in HT1080 fibrosarcoma cells. FEBS Lett (2004) 0.84
Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. Bioorg Med Chem (2006) 0.84
Assessment of gelatinase expression and activity in articular cartilage. Methods Mol Med (2007) 0.83
Endothelial nitric oxide synthase gene polymorphism and ischemic heart disease. Am Heart J (2004) 0.83
Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity. Eur J Dermatol (2006) 0.83
LPS activates ADAM9 dependent shedding of ACE from endothelial cells. Biochem Biophys Res Commun (2012) 0.82
The higher incidence of squamous cell carcinoma in renal transplant recipients is associated with increased telomere lengths. Hum Pathol (2006) 0.82
Modulation of integrin α4β1 by ADAM28 promotes lymphocyte adhesion and transendothelial migration. Cell Biol Int (2011) 0.82
Two novel determinants of etoposide resistance in small cell lung cancer. Cancer Res (2011) 0.82
Peptide aptamers as new tools to modulate clathrin-mediated internalisation--inhibition of MT1-MMP internalisation. BMC Cell Biol (2010) 0.81
Investigation of the role of Endo180/urokinase-type plasminogen activator receptor-associated protein as a collagenase 3 (matrix metalloproteinase 13) receptor. Biochem J (2002) 0.81
MT1-MMP hemopexin domain exchange with MT4-MMP blocks enzyme maturation and trafficking to the plasma membrane in MCF7 cells. Biochem J (2006) 0.81
Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice. PLoS One (2013) 0.80
Golgi reassembly stacking protein 55 interacts with membrane-type (MT) 1-matrix metalloprotease (MMP) and furin and plays a role in the activation of the MT1-MMP zymogen. FEBS J (2010) 0.80
Increased ERK signalling promotes inflammatory signalling in primary airway epithelial cells expressing Z α1-antitrypsin. Hum Mol Genet (2013) 0.78
Characterization of the AB loop region of TIMP-2. Involvement in pro-MMP-2 activation. J Biol Chem (2006) 0.78
Metalloproteinase-dependent and -independent processes contribute to inhibition of breast cancer cell migration, angiogenesis and liver metastasis by a disintegrin and metalloproteinase with thrombospondin motifs-15. Int J Cancer (2014) 0.78